Clinical Trial

A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the safety、tolerability and preliminary efficacy of B019 in subjects with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-06; most recent amendment 2026-04-29.
Trial Details
NCT Number NCT06970496
Lead Sponsor Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Conditions Relapsed or Refractory B Cell Non Hodgkin Lymphoma
Enrollment 48 participants
Start Date 2026-08-31
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-14